Topical treatment of chronic wounds by Woelfel, Joseph A.
University of the Pacific
Scholarly Commons
School of Pharmacy and Health Sciences Faculty
Articles
Thomas J. Long School of Pharmacy and Health
Sciences
1-1-2006
Topical treatment of chronic wounds
Joseph A. Woelfel
University of the Pacific, jwoelfel@pacific.edu
Follow this and additional works at: https://scholarlycommons.pacific.edu/phs-facarticles
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Article is brought to you for free and open access by the Thomas J. Long School of Pharmacy and Health Sciences at Scholarly Commons. It has
been accepted for inclusion in School of Pharmacy and Health Sciences Faculty Articles by an authorized administrator of Scholarly Commons. For
more information, please contact mgibney@pacific.edu.
Recommended Citation
Woelfel, J. A. (2006). Topical treatment of chronic wounds. Pharmacist’s Letter & Prescriber’s Letter, 22(1), 1–8.
https://scholarlycommons.pacific.edu/phs-facarticles/38
 More... 
Copyright © 2006 by Therapeutic Research Center 
Pharmacist’s Letter / Prescriber’s Letter ~ P.O.  Box 8190, Stockton, CA 95208 ~ Phone:  209-472-2240 ~ Fax:  209-472-2249 
www.pharmacistsletter.com ~ www.prescribersletter.com  
 
 
 
    
 
Detail-Document #220175 
−This Detail-Document accompanies the related article published in− 
PHARMACIST’S LETTER / PRESCRIBER’S LETTER 
January 2006 ~ Volume 22 ~ Number 220175
 
 
Topical Treatment of Chronic Wounds 
 
Chronic wounds most commonly include pressure ulcers (also called decubitus ulcers or bed sores), diabetic foot ulcers, burns, and varicose ulcers.  They are 
generally difficult to heal and are often resistant to therapy.1   
Most pressure ulcers occur in the lower part of the body.  The elderly and bedridden spinal cord injury patients are prone to these ulcers.  Common complications 
include osteomyelitis, sepsis, and death.1   
Measures to prevent pressure ulcers include recognizing patients at-risk, reducing bed rest, reducing constant pressure, assessing and maintaining nutritional 
status, and preserving skin integrity.  Treatment is often based on the extent of the wound.  Staging of ulcers is a common practice and relates to ulcer depth.  Stage 1 
is identified by nonblanchable redness of intact skin.  Stage 2 is characterized by ulcer extension through the epidermis or dermis.  Stage 3 ulcers extend through the 
full thickness of the skin into the subcutaneous tissue and create a crater.  Stage 4 effects include tissue necrosis with muscle, bone, or underlying structural damage.   
Treatment of ulcers involves: 1.) daily assessment, 2.) cleaning with sterile saline at each dressing change, 3.) use of occlusive, vapor-permeable or hydrocolloid 
dressings, 4.) use of debriding techniques or medications to remove necrotic tissue, and 5.) use of topical antibiotics for local colonized infection.2 
 
Agent Indication3 Cost3,4** Comments3,4 
Enzymatic Chemical Debridement 
 Papain, Urea  
(Accuzyme, EtheZyme, etc.) 
available as an ointment 
 Papain, Urea, Chlorophyllin 
Copper Complex 
(Panafil, Ziox, etc.) available 
in an ointment or spray 
 Pressure ulcer, stage 2 to 4 
 Burn eschar 
 Diabetic foot ulcer 
 Varicose ulcer 
 
 $54.55 
30 gm tube 
($1.81/gm) 
 $88.00 
30 gm tube 
($2.93/gm) 
 
 Papain is the proteolytic enzyme that debrides necrotic, 
nonviable tissue.  Viable tissue is unharmed. 
 Urea supplements papain action by exposing sulfhydryl 
groups in necrotic tissue to papain action. 
 Chlorophyllin Copper Complex inhibits hemagglutination 
and inflammatory properties of protein degradation 
products.  It promotes healthy granulation, decreases 
inflammation, and reduces wound odor. 
 Papain/urea ointment has been shown to have greater 
efficacy than collagenase ointment.1,5  
 Products vary in papain content which may affect 
efficacy.  Accuzyme contains 830,000 units per gm.  
Panafil contains 521,700 units per gm. 
 Do not use peroxide or heavy metal containing agents due 
to papain inactivation (e.g. zinc containing products, silver 
sulfadiazine creams). 
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Agent Indication3 Cost3,4** Comments3,4 
 Collagenase 
(Santyl) available as an 
ointment 
 Pressure ulcer, stage 2 to 4 
 Burn eschar 
 Diabetic foot ulcer 
 Varicose ulcer 
$60.35 
30 gm tube 
($2.01/gm) 
 Collagenase is specific for digestion of collagen in 
necrotic tissue.  Collagen composes about 75% of dry 
tissue.   
 Optimal pH for enzymatic action is 6 to 8; avoid acidic 
agents for cleansing. 
 Peroxide does not affect its efficacy. 
 Do not store above 77 degrees F. 
 
 Trypsin, Castor Oil, Peru 
Balsam 
(Granulex, Xenaderm) 
available as a spray 
 Pressure ulcer, stage 1 to 4 
 Burn eschar 
 Varicose ulcer 
 
$19.41  
113 gm spray 
($0.17/gm) 
 Trypsin is a mild debriding agent for necrotic tissue. 
 Castor oil and Peru Balsam are protectants providing a 
soothing, protective barrier.  Peru Balsam also reduces 
wound odor. 
 Trypsin/Peru balsam/castor oil was not better than 
mechanical gauze debridement as shown in one study.1,6 
 
Iodine Compounds 
 Cadexomer Iodine available 
as a gel (Iodosorb) or as a 
sheet (Iodoflex) 
 
 
 Chronic non-healing, 
exuding wounds such as 
pressure or leg ulcers, 
exuding, infected wounds 
$59.77 
40 gm gel 
($1.49/gm) 
$49.83 
1x3 sheet 
($16.61/sheet) 
 Contraindicated in patients with iodine sensitivity, 
Hashimoto’s thyroiditis, non-toxic nodular goiter, and in 
children. 
 Potential risk of interaction with lithium due to systemic 
absorption of cadexomer iodine. 
 May accelerate rate of wound healing, reduce pain, help 
remove exudate, and stimulate granulation tissue 
formation.9 
 
Regrowth Stimulants 
 Becaplermin, rh-PDGF 
(Regranex) available as a gel 
 Pressure ulcer, stage 2 to 
4* 
 Diabetic foot ulcer 
$595.56  
15 gm tube 
($39.70/gm) 
 PDGF is a recombinant formulation of platelet-derived 
growth factor which promotes cell mitogenesis and 
protein synthesis for granulation tissue formulation. 
 Adequate blood supply to the affected area is needed for 
efficacy. 
 Efficacy is dependent on absence of necrotic tissue. 
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Agent Indication3 Cost3,4** Comments3,4 
 
 Phenytoin (Dilantin) 
prepared as a suspension of 
the contents of a 100 mg 
capsule mixed with 5 mL 
sterile saline or powder 
applied directly to wound 
 Pressure ulcer, stage 2* 
 Burn eschar* 
 Diabetic foot ulcer* 
 Varicose ulcer* 
$34.84 
100 capsule 
bottle 
($0.35/capsule) 
 Phenytoin may stimulate proliferation of fibroblasts, 
enhance granulation tissue, decrease wound exudate, 
promote collagen deposition, and decrease bacterial 
contamination.7 
 Topical phenytoin appears to be effective and safe for 
healing soft tissue wounds [Evidence level B, lower 
quality RCT]. 7,8 
 
 
Topical Antibiotics 
 Bacitracin, Neomycin, 
Polymyxin B (Neosporin)  as 
an ointment or cream 
 Bacitracin, Polymyxin B 
(Polysporin) as an ointment 
 Prevention or treatment 
of superficial infection 
$6.36 
30 gm tube 
($0.21/gm) 
$6.78 
30 gm tube 
($0.23/gm) 
 
 
 Ointment dosage forms are difficult to remove.   
 May have cytotoxic effects which may delay wound 
healing.  
 Allergic reactions may occur.  
 Bacteria may become resistant with prolonged use. 
 Gentamicin (Garamycin) 
available as an ointment or 
cream 
 
 Prevention or treatment 
of superficial skin and 
soft tissue infections due 
to susceptible gram-
negative and gram-
positive organisms. 
 
 
$3.60 
15 gm tube 
(generic) 
($0.24/gm) 
 Ointment dosage forms are difficult to remove.   
 May have cytotoxic effects which may delay wound 
healing.  
 Allergic reactions may occur.  
 Bacteria may become resistant with prolonged use. 
 Silver Sulfadiazine 
[Silvadene, SSD, Dermazin 
(Canada)] available as a 
cream 
 Prevention of infection in 
second and third degree 
burns 
 Prevention or treatment 
of infection in chronic 
wounds* 
$14.68 
1% 85 gm jar 
(generic) 
($0.17/gm) 
 May have cytotoxic effects which may delay wound 
healing.  
 Allergic reactions may occur.  
 Bacteria may become resistant with prolonged use. 
 Do not use with papain-containing enzymatic debriding 
agents. 
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Agent Indication3 Cost3,4** Comments3,4 
Wound Cleansers 
 Sterile Saline (Normal Saline 
for Irrigation, 0.9%) 
 General wound cleaning 
and rinsing 
Not available  Best for general wound cleaning and rinsing. 
 Note: avoid other wound cleaners such as povidone iodine 
(Betadine), chlorhexidine gluconate (Hibiclens), 
hypochlorite solution (Dakin’s Solution), benzalkonium 
chloride solution, acetic acid solution. They can disturb 
granulation tissue and  be cytotoxic if not diluted or used 
too vigorously.1 
 Hydrogen peroxide 3% solution may delay healing but 
20% solution acts as a healing enhancer.1 
* non-FDA-approved indication 
** Cost information is approximate as of the time this chart was prepared. It is based on manufacturer stated internet website prices, observed retail 
pharmacy prices, and www.drugstore.com listings. Actual selling prices may differ.
 
 
 
 
Users of this document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our editors have researched the information with input from experts, government agencies, and national 
organizations.  Information and Internet links in this article were current as of the date of publication. 
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Levels of Evidence 
In accordance with the trend towards Evidence-Based Medicine, we are citing 
the LEVEL OF EVIDENCE for the statements we publish. 
 
Level Definition 
A High-quality randomized controlled trial (RCT) 
 High-quality meta-analysis (quantitative 
systematic review) 
B Nonrandomized clinical trial 
 Nonquantitative systematic review 
 Lower quality RCT 
 Clinical cohort study 
 Case-control study 
 Historical control 
 Epidemiologic study 
C Consensus 
 Expert opinion 
D Anecdotal evidence 
In vitro or animal study 
Adapted from Siwek J, et al.  How to write an evidence-based clinical review article.  Am Fam 
Physician 2002;65:251-8. 
 
Project Leader in preparation of this Detail-Document: Joseph A. 
Woelfel, Ph.D., FASCP, R.Ph., Assistant Editor 
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